Last updated: 2026-09-05 22:08:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Align Technology Inc. (ALGN) operates in the ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES sector and is listed on NASDAQ. The stock is currently priced at $158.62, with a market capitalization of $11.36B and a P/E ratio of 27.25. Over the past 52 weeks, its price has ranged from $122.00 to $200.44. This page covers its latest market performance, valuation, price trends and company information.
$11.36B | |
$157.67 | |
$737.45 | |
$4.88 | |
$159.85 | |
449.47K | |
965.58K | |
27.25 | |
$200.44 | |
$122.00 | |
-- | |
-- |
Align Technology Inc. (ALGN) last closed at $159.86 as of 2026-09-04 23:31:00, unchanged from the previous close of $159.86.
During the latest regular trading session, ALGN traded between $4.88 and $737.45, with a volume of 449.47K shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, Align Technology Inc. (ALGN) moved from $158.84 to $158.62, representing a decline of 0.14% ($0.22).
The stock traded between $153.98 and $162.92 during the period. The latest price is near the middle of the 7-day range, indicating range-bound.
The average daily volume was 856.07 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 46.7%
ALGN is currently trading at $158.62, placing it 46.7% of the way from its 52-week low of $122.00 to its 52-week high of $200.44. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.
| Industry | ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES |
| Employees | 20435 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Align Technology Inc. (ALGN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.